Compare Samsara Inc (IOT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs ResMed Inc. — how do they compare? Samsara Inc trades at $41.51 (market cap $24.14B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while Samsara Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and ResMed Inc. for 51 Days on average.
| IOT | RMD | |
|---|---|---|
Market Cap | $24.14B | $31.89B |
Volume | 5,372,580 | 618,314 |
Sector | Technology | Health |
52-Week High | $45.22 | $277.88 |
52-Week Low | $24.25 | $182.82 |
Typical Hold Time | 19 Days | 51 Days |
Enterprise Value | $23.38B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $40.51, down 2.95% on the day, yet maintains a bullish technical trend with strong analyst support. The company reported robust Q2 2027 results, beating EPS estimates with $0.20 versus $0.16 expected, and achieved 30% year-over-year revenue growth. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion. The stock is supported by a consensus price target of $51.15, indicating significant upside potential from current levels.
The outlook for IOT is positive, driven by strong earnings momentum and large-customer adoption, though high valuation multiples (P/E 274.8, P/S 13.01) pose a risk if growth slows. Investors face execution risks amid competitive pressures, but institutional accumulation and a 75% buy rating from analysts suggest confidence in sustained growth. Key catalysts include continued revenue expansion and margin improvement, while monitoring cash flow trends remains critical.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
